Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Mar 1;26(5):938–951. doi: 10.1091/mbc.E14-06-1158

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 Basu et al. This article is distributed by The American Society for Cell Biology under license from the author(s). Two months after publication it is available to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).

“ASCB®,” “The American Society for Cell Biology®,” and “Molecular Biology of the Cell®” are registered trademarks of The American Society for Cell Biology.

PMC Copyright notice

FIGURE 7: — LL5β knockdown and CytoD treatment differentially affect frequency, duration, and GFP fluorescence intensity of AChR vesicle fusions. All methods and parameters as defined in Figure 6. Bars give means ± SE. (A–C) LL5β-knockdown myotubes. Note the reduction of fusion numbers during 30-s observation period upon LL5β knockdown without changes in duration and intensity of fusion events. The relative number of double fusions at the same sites was not affected (see text). N = 12 cells for control and 14 for cells for LL5β-knockdown myotubes. Means ± SE. *p < 0.05. (D–F) CytoD-treated myotubes. Note stronger reduction of fusion numbers during 30-s observation period upon CytoD treatment, with significant reduction in duration but not intensity of fusion events. Means ± SE. N = 14 cells for control and 14 cells for CytoD-treated myotubes. **p < 0.001, ***p < 0.0001.